Comparative Pharmacology
Head-to-head clinical analysis: NEUPRO versus PARLODEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEUPRO versus PARLODEL.
NEUPRO vs PARLODEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rotigotine is a non-ergoline dopamine agonist with high affinity for dopamine D1, D2, D3, D4, and D5 receptors; also binds to serotonin 5-HT1A and alpha2-adrenergic receptors.
Dopamine D2 receptor agonist; inhibits prolactin secretion by binding to pituitary and hypothalamic D2 receptors.
Apply transdermally once daily; initial dose 2 mg/24h, titrated weekly by 2 mg/24h up to 6 mg/24h, maximum 8 mg/24h.
Parkinson disease: initial 1.25 mg orally twice daily, increase by 2.5 mg/day every 2-4 weeks; usual range 15-30 mg/day. Hyperprolactinemia: initial 1.25-2.5 mg orally once daily, titrate to 2.5 mg twice daily; maintenance 2.5-15 mg/day.
None Documented
None Documented
Single dose: 5-7 hours (transdermal); steady state: 7-10 hours; effective half-life for dosing is 8 hours due to reservoir in skin
Terminal elimination half-life: 12-14 hours (biphasic, initial half-life 6-8 hours); clinical context: steady-state achieved in 2-3 days.
Renal: 45% (metabolites), Fecal: 40% (metabolites), Biliary: 15%
Renal: approximately 60% as metabolites, 6% as unchanged drug; biliary/fecal: approximately 40% as metabolites and unchanged drug.
Category C
Category C
Dopamine Agonist
Dopamine Agonist